Default company panoramic image

Rna Diagnostics Inc.

Rna Diagnostics solves a high priority problem in cancer treatment with the first real time chemotherapy guidance tool.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded March 2010
  • Employees 10
  • Website

Company Summary

Rna Diagnostics has developed real-time cancer chemotherapy guidance tools. The RNA Disruption Assay (RDA™) is the only diagnostic tool that predicts early in treatment how a patient will respond to chemotherapy. Reduction of unnecessary chemotherapy is a top priority for breast oncologists. RDA™ improves patient outcomes while lowering breast cancer treatment cost.


  • Default avatar
    Amadeo, PhD Parissenti

    Professor of biochemistry at Laurentian University. Over 20 years experience studying tumour resistance to chemotherapy.

  • Default avatar
    John Jordan, MBA, CMA, CPA/ABV (US)

    Financial executive with 15 years experience taking early stage technology companies from start-up through to successful exit

  • Default avatar
    Kenneth, MD, FRPCP Pritzker

    Former Chief, Pathology & Lab Medicine at Mount Sinai Hospital, Toronto. Internationally recognized leader in molecular diagnostics

  • Default avatar
    John Connolly, MBA
    VP Corporate Development

    20 year entrepreneur in medical technology business development , former patrner at MDS Capital Corp, Health Science venture capital investor


  • Default avatar
    Stikeman Elliott

Previous Investors

  • Default avatar
    Niagara Angels, Ontario Centres of Excellence
  • Default avatar
    York Angel Investors